Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
One study found that exenatide, a GLP-1 agonist that was approved to treat Type 2 diabetes back in 2005, significantly reduced the alcohol-cue reactivity in the area of the brain related to drug reward and addiction and significantly reduced the total alcohol intake in patients with obesity in particular
For glycemic control in type 2 diabetes, the SURPASS trials showed sustained A1C reductions over 40-52 weeks across all dose levels
La jugabilidad, la navegacin intuitiva y la optimizacin para distintos tamaos de pantalla permiten que la experiencia sea fluida
At 5mg/mL, 20 units equals 1mg
Your GP may recommend specialist referral to NHS Tier 3 weight management services or an endocrinologist for further assessment and support
The injectables use the same active ingredients as the branded versions, which currently are in short supply in some doses
US$ 26.36
US$ 22.68
US$ 26.06
US$ 26.49
US$ 24.28
US$ 29.52
US$ 24.48
